Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05696795 · ClinicalTrials.gov registry record · Phase 2
Janus Kinase Inhibition in Sarcoidosis
A Phase 2 study of Sarcoidosis, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05696795 is a Phase 2 study of Sarcoidosis that has completed, run by Yale University. The registered enrollment target is 10 participants, below the 2,169-participant average among 21 other Sarcoidosis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05696795, a Phase 2 study of Sarcoidosis, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the role of the oral JAK1 inhibitor, abrocitinib 200 mg once daily, for the treatment of patients with moderate to severe cutaneous sarcoidosis.
Conditions Studied
Interventions
- DRUG Abrocitinib 200 mg
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2025-04-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05696795
The ClinicalTrials.gov registry entry for NCT05696795 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,169-participant average among 21 other Sarcoidosis trials with a reported enrollment target (100% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sarcoidosis appearing as the primary indexed condition, and to 1 intervention - of which Abrocitinib 200 mg is the first listed.
NCT05696795 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT05696795 about?
NCT05696795 is a clinical study titled "Janus Kinase Inhibition in Sarcoidosis". The purpose of this study is to investigate the role of the oral JAK1 inhibitor, abrocitinib 200 mg once daily, for the treatment of patients with moderate to severe cutaneous sarcoidosis.
What is the current status of trial NCT05696795?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2023-06-01. Estimated completion is 2025-04-23.
What conditions does trial NCT05696795 study?
This clinical trial studies the following conditions: Sarcoidosis.
What interventions are being tested in trial NCT05696795?
The interventions under investigation include: Abrocitinib 200 mg (DRUG).
Who is sponsoring clinical trial NCT05696795?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05696795 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
COMPLETED · Phase 2
-
Quantification & Classification of Inflammatory Cells in Uveitis Using OCT
RECRUITING
-
Cardiovascular Multimodality Imaging Study
RECRUITING
-
Cardiac Sarcoidosis Randomized Trial
RECRUITING · Phase 3
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
-
Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.